NASDAQ · PYPD
PolyPid Ltd.
$5.59-$0.19 (-3.29%)
PolyPid Ltd.’s quoted price sits in the upper half of its reported 52-week range, 4.28% below the high.
Loading market information…
NASDAQ · RNXT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
RenovoRx, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.47% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
RenovoRx, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.05. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow RenovoRx, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 15, 2025 |
| -$0.080.0% vs estimate |
| $197.00K+7.46% vs estimate |
| Q4 2024 | Mar 31, 2025 | -$0.12+7.69% vs estimate | $43.00K-74.33% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -$0.10+16.67% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.59-$0.19 (-3.29%)
PolyPid Ltd.’s quoted price sits in the upper half of its reported 52-week range, 4.28% below the high.
$1.18+$0.02 (+1.72%)
MAIA Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.01% below the high.
$1.02$0.00 (0.0%)
Annovis Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.45% below the high.
$0.81-$0.03 (-3.13%)
Elutia Inc’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
$0.85-$0.09 (-9.66%)
Celularity Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.69% below the high.
$0.86-$0.02 (-2.73%)
Tvardi Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.83% below the high.
$0.73-$0.04 (-5.52%)
Lantern Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.16% below the high.
$1.75+$0.09 (+5.42%)
CalciMedica, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.14% below the high.
